NGM438

Developed for: breast cancer · cholangiocarcinoma · endocervical carcinoma · esophageal cancer · gastric cancer · head and neck squamous cell carcinoma · melanoma · mesothelioma
+10 more
· non-small cell lung carcinoma · ovarian cancer · prostate cancer · renal cell carcinoma · bladder transitional cell carcinoma · colorectal cancer · colorectal carcinoma · malignant exocrine pancreas neoplasm · malignant pancreatic neoplasm · urinary bladder cancer
Investigated by: Merck Sharp & Dohme LLC · NGM Biopharmaceuticals, Inc

today NCT05311618 · Ph 1 NCT05215574 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05311618	May 2022 → Apr 2025	breast cancer, cholangiocarcinoma, colorectal cancer, endocervical carcinoma +11	NGM Biopharmaceuticals, Inc	Unknown	No outcome recorded
Phase 1	NCT05215574	Mar 2022 → Jul 2025 overdue	bladder transitional cell carcinoma, breast cancer, cholangiocarcinoma, colorectal carcinoma +11	NGM Biopharmaceuticals, Inc	Active not recruiting	No outcome recorded

Date	Issuer	Release
2022-05-12	NGM Biopharmaceuticals, Inc	NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors ngmbio.com ↗
2020-12-09	NGM Biopharmaceuticals, Inc	NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors ngmbio.com ↗

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	NGM438	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215574 ↗ 1 NCT05311618 ↗
Route	Intravenous	“NGM438 is given intravenously (IV)” NCT05215574 ↗